P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer - Wikidata - wikimedia - TriplyDB

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

http://www.wikidata.org/entity/Q36538788

about

TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.TrkA is a binding partner of NPM-ALK that promotes the survival of ALK+ T-cell lymphoma.Alectinib for ALK-positive non-small-cell lung cancer.Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.Developments in pharmacotherapy for treating metastatic non-small cell lung cancer.Targeting ALK: Precision Medicine Takes on Drug Resistance.Multiple resistance to carcinogens and xenobiotics: P-glycoproteins as universal detoxifiers.Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib.The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.[Targeted therapy and precision medicine : More than just words in the treatment of lung cancer].Treating ALK-positive non-small cell lung cancer.Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis

P2860

Q33911863-F5628A47-14A1-43D9-94BB-5A5539716326 Q36114660-3072CC17-E284-47DC-A1EF-E420DED7EB81 Q38663460-182DA1A1-7042-47AC-8DA8-F1FFFD63ACE8 Q38756797-470A9C60-46CF-484E-AC36-2F6A9BE09FC9 Q38846027-95D185DB-2E68-4E69-9892-894D510DD48C Q39039088-23BF69F3-5CFC-4DD0-9644-F461C4435387 Q39076364-01984351-C12B-4783-B48D-187B33A18DC3 Q39103431-F1AFDF7F-CB0E-4280-AD80-382400B531AF Q39125345-E110B17E-5D5F-4DB1-A926-A4DC24721BEF Q39128273-2028FB69-2502-43AF-ABBE-97C547203B4F Q39278116-249FA16F-64B8-45C8-9529-118DC14BF759 Q41636404-5DE75D8B-8A22-4185-971A-DA078EAD2228 Q42344252-46E1801F-DC06-4354-BC9A-1AE7FCEF7B2C Q46071509-507E33D8-85E3-46B4-ABB4-688C7720609D Q47777234-7F7A52FF-DE47-4790-9A48-2DAE8ACEEE57 Q49887874-5EFFB0CE-8BEE-433A-A87A-A2CBAE03977C Q50040968-AED81D0E-CCD8-49ED-860E-607B71BC3CBB Q50043843-8D148EAE-6845-46DC-98E5-B70360EBCC85 Q51066547-D8425191-8971-4FDC-A946-7A1DC62AE0BE Q51740588-45C456A3-CDBB-450F-B73B-B06F88F2A3B8 Q52679023-384F2EAC-333B-4B06-A6C6-918A07A90929 Q54176392-83D5954B-4657-4965-8C67-8148A96B2595 Q54967334-106821A4-DD6F-422B-BAE0-07653DA5518A Q54977783-F4235E13-D368-4962-BEE3-6658A6271AE3 Q57168071-DEAFB1DB-2529-4340-9732-04BCDF058017 Q58714854-9D6D1F76-B532-4504-9FE1-D65F8E06059C

P2860

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer

http://www.wikidata.org/entity/Q36538788

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

P-glycoprotein Mediates Ceriti ...... ged Non-small Cell Lung Cancer

@ast

P-glycoprotein Mediates Ceriti ...... ged Non-small Cell Lung Cancer

@en

type

label

P-glycoprotein Mediates Ceriti ...... ged Non-small Cell Lung Cancer

@ast

P-glycoprotein Mediates Ceriti ...... ged Non-small Cell Lung Cancer

@en

prefLabel

P-glycoprotein Mediates Ceriti ...... ged Non-small Cell Lung Cancer

@ast

P-glycoprotein Mediates Ceriti ...... ged Non-small Cell Lung Cancer

@en

P1433

Q36538788-A14A7E5E-AB1E-477B-898C-81051C759AC5

P1476

Q36538788-DB10DF72-53D9-4B68-AF50-C9E5FE844FED

P2093

Q36538788-0DE307A2-1AA3-49BB-BBA1-17859C96A92B

Q36538788-1A38F184-035B-4561-BB46-9F355BD9AF50

Q36538788-1FE9EC72-4E0F-4C9A-A878-B88EAD81D687

Q36538788-39285602-458E-4111-A607-8B2C8201F1FD

Q36538788-3AE53FDF-8BEB-4A39-B4DB-098738E64B82

Q36538788-4A8F40BD-2192-4628-BAE5-3B9402BDCDAA

Q36538788-6B8F08BF-EF6B-4D62-806E-C92C8B2CE645

Q36538788-7324569A-5F0C-4E09-B208-280A71F2DA1B

Q36538788-7D2C029A-F711-4696-80F4-B485AC53FB25

Q36538788-86D8075F-4A54-4278-A9E6-D4C72F09DEF1

P2860

Q36538788-1D2F9DA4-B41F-4C32-BFEA-12DA2F3C9C8B

Q36538788-236B4979-7094-4109-AB10-6EA12DF23C27

Q36538788-2A1212D8-701C-4070-98B8-39C84C48C9E2

Q36538788-2CCEEC92-8159-493B-AE75-A7B40CE8EBE0

Q36538788-3371C560-8AAE-4EE6-9F2C-04873F51F4F4

Q36538788-4F53464C-75F2-47D9-8FC9-2427FECF3AC2

Q36538788-59F1C680-C598-4E1F-8BAB-3491C0D0CCA0

Q36538788-5CDB8344-3A83-4A33-B16A-3CD7956B0DDD

Q36538788-61D3E7DD-1846-4390-ACF3-1EE500781B43

Q36538788-64718E21-D1C4-4B91-A21D-11869614C961

P304

Q36538788-86FCDB3C-7673-4707-BFFF-447FDBF78C0F

P31

Q36538788-4DB9A49B-44D1-44A4-A06E-331A6B4412FF

P356

Q36538788-B1703DE7-1447-443B-B5E0-A99B682239B2

P478

Q36538788-463C512B-AA8A-4C58-9EED-BF91E5743752

P50

Q36538788-4566808E-AFA1-48C4-8D53-BCF2BF06C8B0

Q36538788-4C961378-57CA-4C65-BE44-934351EBFD4B

Q36538788-B7DBFC23-3425-4FC9-BD58-12B5860B97F8

Q36538788-DBBE2B8D-9094-416A-9A7D-6B26D1013B40

Q36538788-EB8E43F2-40ED-489D-A7FC-615CC0C0E196

P577

Q36538788-4AB0310A-9797-4EDA-80B6-78CCC6F5CDD2

P698

Q36538788-A53C817B-10E5-48C2-86EE-2BB86A5FFF9E

P921

Q36538788-9FA533CF-BB17-4E2B-B496-2B4069D33E1E

P932

Q36538788-02921C9A-3071-48E4-9D21-D83FF3E264BB

P356

J.EBIOM.2015.12.009

P1433

P1476

P-glycoprotein Mediates Ceriti ...... ged Non-small Cell Lung Cancer

@en

P2093

A John Iafrate

http://www.w3.org/2001/XMLSchema#string

Akito Dobashi

http://www.w3.org/2001/XMLSchema#string

Alice T Shaw

http://www.w3.org/2001/XMLSchema#string

Atsushi Horiike

http://www.w3.org/2001/XMLSchema#string

Hironori Ninomiya

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

Justin F Gainor

http://www.w3.org/2001/XMLSchema#string

Makoto Nishio

http://www.w3.org/2001/XMLSchema#string

Mari Mino-Kenudson

http://www.w3.org/2001/XMLSchema#string

Noriko Yanagitani

http://www.w3.org/2001/XMLSchema#string

P2860

A distinct "side population" of cells with high drug efflux capacity in human tumor cells

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

P304

54-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EBIOM.2015.12.009

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Ryohei Katayama

P577

2015-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26870817

http://www.w3.org/2001/XMLSchema#string

P921

P932

4739423

http://www.w3.org/2001/XMLSchema#string